Bayer, Brigham and Women’s Hospitals BWH.
and Massachusetts General Hospital MGH has worked to treat chronic lung diseases. The partners will operate out of a joint laboratory located in Boston at BWH that will receive more than $ million over the next five years.
In the joint laboratory, people from three organizations will work in joint teams. Bayer will contribute people with drug discovery and development skills to support them. BWH and MGH will potentially contribute people with complementary clinical expertise and knowledge of disease mechanisms. Bayer, BWH and MGH will share any research findings equally.
Bayer and his associates have identified four people involved in the initiative.
Edwin Silverman and Bruce Levy are representing BWH. MGH has put forward Benjamin Medoff, while Bayer is contributing to the expertise of Marcus Koch, who leads his preclinical research in lung diseases.
Like this story? Subscribe to FierceBiotech!
Biopharma is a fast-growing world where big ideas come every day. Our customers rely on FierceBiotech as their reading source for the latest news, analysis, and data in the world of biotech and pharma R&D. Sign up today to receive biotech news and updates delivered to your inbox and read further.
This initiative builds joint laboratories with Bayer’s years of experience. In May, Bayer formed an immuno-oncology lab with the German Cancer Research Center. Recently, Bayer established its first joint laboratory in Boston, paving the way for collaboration with BWH and MGH.
Bayer’s new partners have bought into the joint lab concept.
We strongly believe that this model will significantly accelerate the pace of discovery from the laboratory toward the goal of safely and efficiently receiving new treatments to patients, Paul Anderson, BWH’s chief academic officer, said in a statement. This collaboration provides an opportunity to directly integrate novel findings into the drug development pipeline, thus accelerating the time to transfer a new treatment to the clinic.
The collaboration continues Bayer’s Boston expansion. Earlier this year, Bayer planned to set up in Kendall Square, giving it laboratory and office space in a biotech hot spot. That commitment focused on cardiovascular diseases after the creation of a joint laboratory with MIT and Harvard’s Comprehensive Institute.